Bavarian Nordic wins EU approval for Imvanex mpox vaccine in children 2-11

Reuters2026/08/07 06:01

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Bavarian Nordic won European Commission clearance to extend IMVANEX (MVA-BN) use to children aged 2 to under 12.
The EU label now covers people aged 2 and older for protection against mpox, smallpox, and vaccinia virus disease.
Decision follows a Phase 2 study in 227 children showing immune responses non-inferior to adults with a similar safety profile.
The trial was co-funded by the Coalition for Epidemic Preparedness Innovations.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bavarian Nordic A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608070200OMX_____CNEWS_EN_GNW1001256491_en) on August 07, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Bavarian Nordic wins EU approval for Imvanex mpox vaccine in children 2-11

You may also like

Crypto prices